Opko Health, Inc. · NASDAQ:OPK
Opko Health — Q2 2026 Earnings Presentation
13 slides from Opko Health's earnings presentation, Jul 27, 2026
Slide 1: Next-generation solutions for serious diseases across established global markets
Next-generation solutions for serious diseases across established global markets OPKO HEALTH CORPORATE PRESENTATION May 2026 | NASDAQ: OPK NASDAQ: OPK
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements," as that term is defined profitability will be successful, whether our strategic efforts to grow the Company under the Private Securities Litigation Reform Act of 1995 (PSLRA), which will ultimately be successful and
Slide 3: Driving Long-term Growth & Value
Driving Long-term Growth & Value Global Therapeutics Diagnostics Enhanced Pharmaceutical Pipeline Streamlined for Financial Strength Business with Progression Growth & with Disciplined Sales & Expansion Profitability Capital Allocation Momentum NASDAQ: OPK | 3
Slide 4: Proprietary Technologies
Proprietary Technologies ModeX platforms validated through partnerships and clinical-stage programs M U LT I S P E C I F I C A N T I B O D I E S • Designed to bind to 2 T-cell antigens and 2 tumor antigens • Offers greater specificity than existing I/O treatments IMMUNO-ONCOLOGY • Broad potential ap
Slide 5: Product Pipeline
Product Pipeline | Promising portfolio with five assets in clinical stage and five pre-IND assets PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNER EBV Nanoparticle Vaccine Prevention of EBV-related Diseases MDX2201 CD3/CD28/cMET/Trop2 Solid Tumors MDX2001 Tetraspecific T-Cell Engager I
Slide 6: Partnerships and Business Development
Partnerships and Business Development OPKO has formed productive partnerships to share development costs and leverage commercial capabilities BARDA EBV NANOPARTICLE COVID-19 / FLU DISCOVERY OF HUMAN GROWTH LONG-ACTING VACCINE MULTISPECIFICS MULTISPECIFIC ANTIBODIES HORMONE BIOLOGICS & PEPTIDES NOW E
Slide 7: NGENLA Poised to Capture Significant Share of Growing Global hGH Market
NGENLA Poised to Capture Significant Share of Growing Global hGH Market Once-weekly administration supplanting daily injections PROUDLY PARTNERED WITH PFIZER E X PA N D I N G S H A R E O F G R O W I N G M A R K E T L A U N C H E D G L O B A L LY $14.3B $32M 2025 FY gross profit share earned of NGENL
Slide 8: Pharmaceutical Product Sales
Pharmaceutical Product Sales Global business lines with growing revenues and meaningful cash flow Specialty Sustained Sales Pharmaceutical of CKD Therapy Products • Global operations focused on sales of specialty • Deeper integration with Nicoya supports pharmaceuticals and other healthcare products
Slide 9: BioReference Health: Streamlined Operations
BioReference Health: Streamlined Operations A recalibration of the organization and its cost structure position BioReference for growth and profitability Divestiture of • Up to $462.5M1 cash from two asset sales Certain Assets to representing ~$200M in annual revenues Labcorp (~40% of business befor
Slide 10: Disciplined Capital Allocation
Disciplined Capital Allocation $341M in cash as of March 31, 2026 ENHANCED R&D RETURN CAPITAL FINANCIAL POSITION INVESTMENT TO SHAREHOLDERS Restructured balance sheet and Funding R&D to advance Share repurchases to enhance asset sales expected to provide pipeline into and through shareholder value a
Slide 11: Leadership Team with Unprecedented Experience
Leadership Team with Unprecedented Experience Phil Frost Jane Hsiao Elias Zerhouni Gary Nabel John Mascola Chief Executive Officer Chief Technical Officer President and Vice Chief Innovation Officer Chief Scientific Officer, and Chairman and Vice Chairman Chairman and Director; CEO, ModeX ModeX • Fo
Slide 12: Priorities to Generate Long-Term Value
Priorities to Generate Long-Term Value Focused on execution of strategic priorities to produce clinical and financial success Therapeutics Global Focused Diagnostics Enhanced Pipeline Progression Pharmaceutical Positioned for Growth Financial + Expansion Business Growth & Profitability Strength • Pr
Slide 13: www.opko.com
www.opko.com NASDAQ: OPK NASDAQ: OPK